Represented Chardan Capital Markets, LLC as placement agent in the SEK70 million directed share issue of Nasdaq Stockholm-listed NeuroVive Pharmaceutical AB, a mitochondrial medicine company developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection. The transaction was conducted as a private placement in the United States and involved a share loan facility by certain of NeuroVive’s existing principle stockholders.
-
副主席兼纽约办公室管理合伙人;资本市场及公司业务部联席主席;亚洲业务部主席”; 纽约,北京
-
合伙人